Modulating oncogenic KRAS expression in pancreatic cancer cells demonstrated distinct rewiring of central carbon metabolism to shift glycolytic intermediates into bioenergetic pathways and a preferential use of glutamine for tricarboxylic acid (TCA) cycle metabolism6,7. The gene discussed is KRAS; the disease is pancreatic neoplasm.